| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11147817 | SHILPA | Pharmaceutical composition of pemetrexed |
Mar, 2035
(11 years from now) | |
Pemetrexed is owned by Shilpa.
Pemetrexed contains Pemetrexed Disodium.
Pemetrexed has a total of 1 drug patent out of which 0 drug patents have expired.
Pemetrexed was authorised for market use on 22 May, 2023.
Pemetrexed is available in solution;intravenous dosage forms.
The generics of Pemetrexed are possible to be released after 26 March, 2035.
Drugs and Companies using PEMETREXED DISODIUM ingredient
Market Authorisation Date: 22 May, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
PEMETREXED family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic